GREEN, GRIFFITH & ASSOCIATES - Key Persons
Job Titles:
- Founding Partner
- Local Counsel for Ingenus
Warner Chilcott v. Lupin - Chris was counsel for Lupin in litigation related to Lupin's Abbreviated New Drug Application that seeks approval to market a generic equivalent to Warner Chilcott's Generess Fe® (norethindrone and ethinyl estradiol chewable tablets) product. The district court (Pisano, J.) invalidated the asserted claims, and entered judgment in favor of Lupin.
A founding partner of Green Griffith, Chris has more than 35 years of experience representing clients in the pharmaceutical, chemical, medical device and biotech fields. He has served as lead counsel in cases before both U.S. District Courts and the Court of Appeals for the Federal Circuit. Inter Partes reviews (IPRs) and post-grant proceedings under the AIA, as well as arbitrations and mediations.
A lawyer experienced in both law firm and in-house practice, Don leads clients to balanced business decisions using legal skills and experience developed over 20-plus years of practice…
Job Titles:
- Founding Partner
- Counsel for Opiant Pharmaceuticals, Inc
- Counsel in Defending USV Against Alleged Infringement of Amgen
- Lead Counsel
- Local Counsel for Ingenus
Warner Chilcott v. Lupin - Bob was lead counsel for Lupin in litigation related to Lupin's Abbreviated New Drug Application that was seeking approval to market a generic equivalent to Warner Chilcott's Generess Fe® norethindrone and ethinyl estradiol chewable tablets product. After a district court judgment in favor of Lupin, the matter was settled.
Eli Lilly v. APP Pharmaceuticals - Bob was lead counsel at trial in litigation related to APP Pharmaceutical's Abbreviated New Drug Application that was seeking approval to market a generic equivalent to Eli Lilly's Alimta® pemetrexed product.
A highly-regarded industry leader and founding partner of Green Griffith, Bob's influence extends from the courtroom to corporate board rooms to the shelves of neighborhood drugstores. His work as lead counsel for both plaintiffs and defendants since the 1984 passage of the Hatch-Waxman Act has affected more than 40 drug products.